Approval supported by data from phase III confirmatory trials, VIALE-A and VIALE-C
VIALE-A study showed Venclexta plus azacitidine significantly improved overall survival in newly diagnosed AML compared to azacitidine alone
Supplemental New Drug Applications approved under the FDA's Real-Time Oncology Review pilot programme and Project Orbis initiative